A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening outlook. Click for this EXAS update.

Apax Partners has completed its acquisition of Exact for 730 million euros. Based in The Netherlands, Exact is a business software provider. LONDON–(BUSINESS WIRE)–Private equity group Apax Partners ...

If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock ...

The rumors are now a reality. Abbott Laboratories is acquiring Exact Sciences for $21 billion, marking what could be the biggest medtech deal of 2025. The deal’s announcement comes less than 24 hours ...

Here’s what you should know: 1. Epic will handle multiple components of Exact’s IT system, from “order entry all the way through revenue cycle and customer care,” Exact Sciences CEO Kevin Conroy said ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Abbott has agreed to acquire cancer test-maker Exact ...

Earnings Call Insights: Exact Sciences Corporation (NASDAQ:EXAS) Q4 2024 Kevin Conroy, Chairman and CEO, highlighted Exact Sciences' progress in 2024, including delivering over 4.6 million test ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...